Erratum: BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs (Clin Cancer Res (2015) 21 (1752–1763) DOI: 10.1158/1078-0432.CCR-14-1564);BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs

Clinical Cancer Research

Volumn 21, Issue 7, 2015, Pages 1752-1763

  Liu, Zebing ^a,b   Wei, Ping ^a,b   Yang, Yu ^b   Cui, Wenli ^a,b   Cao, Bing ^a,b   Tan, Cong ^a,b   Yu, Baohua ^a,b   Bi, Rui ^a,b   Xia, Kaiqin ^a,b   Chen, Weixiang ^a,b,c   Wang, Yiqin ^a,b   Zhang, Youyuan ^b   Du, Xiang ^a,b   Zhou, Xiaoyan ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c Shanghai Gongli Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYTOKINE RECEPTOR ANTAGONIST; PF 04217903; PROTEIN BATF2; SCATTER FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; BATF PROTEIN, HUMAN; HGF PROTEIN, HUMAN; MET PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; COLORECTAL NEOPLASMS; DISEASE COURSE; DRUG SCREENING; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENES, TUMOR SUPPRESSOR; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS C-MET; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927631211     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-22-0469     Document Type: Erratum

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Tenbaum SP, Ordóñez-Moŕan P, Puig I, Chicote I, Arqúes O, Landolfi S, et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012;18:892-901.
3. Su ZZ, Lee SG, Emdad L, Lebdeva IV, Gupta P, Valerie K, et al. Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc Natl Acad Sci U S A 2008;105:20906-11.
4. Ma H, Liang X, Chen Y, Pan K, Sun J, Wang H, et al. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int J Cancer 2011;128:771-7.
5. Seol DW, Chen Q, Zarnegar R. Transcriptional activation of the Hepatocyte Growth Factor receptor (c-met) gene by its ligand (Hepatocyte Growth Factor) is mediated through AP-1. Oncogene 2000;19:1132-7.
6. Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin 2010;31:1181-8.
7. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005;94:29-86.
8. Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM, et al. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase-and AKT-dependent pathways. Cancer Res 2000;60:4277-83.
9. Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer 2008;44:641-51.
10. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002;109:863-7.
11. Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, et al. Increased TGF-a as a mechanism of acquired resistance to the Anti- EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res 2013;19:6751-65.
12. Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res 2012;18:737-47.
13. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer. Clin Lung Cancer 2012;5:391-5.
14. Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, et al. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 2012;118:5903-11.
15. Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, et al. Treatment rationale study design for the MetLung trial: a randomized, double-blind phase iii study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patientswhohave received standard chemotherapy for stage IIIB or IV met-positive non-small-cell lung cancer. Clin Lung Cancer 2012;6:500-4.
16. Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol 2013;26:1632-41.
17. Liu Z, Yang Y, Zhang Y, Ye X, Wang L, Xu G. Stomatin-like protein 2 is associated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF-β in thyroid cancer cells. Oncol Rep 2014;31:153-60.
18. Liu Y, Zheng P, Liu Y, Ji T, Liu X, Yao S, et al. An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer. Gut 2013;62:571-81.
19. Wang RY, Chen L, Chen HY, Hu L, Li L, Sun HY, et al. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. Gastroenterology 2013;145:1436-48.
20. Goodwin CR, Lal B, Zhou X, Ho S, Xia S, Taeger A, et al. Cyr61 mediates HGF-dependent tumor cell growth, migration and Akt activation. Cancer Res 2010;70:2932-41.
21. Lee JH, Bae JA, Lee JH, Seo YW, Kho DH, Sun EG, et al. Glycoprotein 90K, downregulated in advanced colorectal cancer tissues, interacts with CD9/ CD82 and suppresses the Wnt/β-catenin signal via ISGylation of β-catenin. Gut 2010;59:907-17.
22. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-57.
23. Dash R, Su ZZ, Lee SG, Azab B, Boukerche H, Sarkar D, et al. Inhibition of AP-1 by SARI negatively regulates transformation progressionmediated by CCN1. Oncogene 2010;29:4412-23.
24. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68.
25. Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, et al. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 2012;143:811-20.
26. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009;15:59-67.
27. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-90.
28. Zou HY, Li Q, Lee JH, Arango ME, Burgess K, Qiu M, et al. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther 2012;11:1036-47.
29. Murphy TL, Tussiwand R, Murphy KM. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat Rev Immunol 2013;13:499-509.
30. Ma H, Chen Y, Hu Z, Mo Q, Tang J, Sun C. Decreased expression of BATF2 is significantly associated with poor prognosis in oral tongue squamous cell carcinoma. Oncol Rep 2014;31:169-74.
31. De Oliveira AT, Matos D, Logullo AF, Da Silva SR, Neto RA, Filho AL, et al. MET is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 2009;29:4807-11.
32. Zagouri F, Bago-Horvath Z, Rössler F, Brandstetter A, Bartsch R, Papadimitriou CA, et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 2013;108:1100-5.
33. Ludes-Meyers JH, Liu Y, Munoz-Medellin D, Hilsenbeck SG, Brown PH. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 2001;20:2771-80.
34. Matthews CP, Colburn NH, Young MR. AP-1 a target for cancer prevention. Curr Cancer Drug Targets 2007;7:317-24.
35. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specifi city. Oncogene 2001;20:2438-52.
36. Maki Y, Bos TJ, Davis C, Starbuck M, Vogt PK. Avian sarcoma virus 17 carries the jun oncogene. Proc Natl Acad Sci U S A 1987;84:2848-52.
37. Ryseck RP, Bravo R. c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins. Oncogene 1991;6:533-42.
38. Yi BR, Park MA, Lee HR, Kang NH, Choi KJ, Kim SU, et al. Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models. Mol Oncol 2013;7:543-54.